Q-omics provides the consensus-scored ACTBP12 profile across patient tissues and cancer cell-line models. ACTBP12 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ACTBP12 is differentially expressed in 3, with the highest sampling consensus in KICH. Additionally, ACTBP12 RNA expression shows 3,529 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, KICH, and STAD as cancer lineages where ACTBP12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTBP12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTBP12 survival associations across molecular data types. ACTBP12 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTBP12 RNA expression–survival associations across cancer types. High ACTBP12 expression shows unfavorable associations in STAD, LUAD, UCEC and GBM, but favorable associations in COAD and CESC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .012). Together, the overview and detailed table identify COAD as the clearest survival context for ACTBP12 RNA expression.
This table summarizes ACTBP12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ACTBP12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTBP12 shows lower tumor expression in KICH, UCEC and READ. The KICH box plot shows higher ACTBP12 RNA expression in normal versus tumor tissue (log2 FC = −0.116, t-test p = .015).
This table shows molecular features associated with ACTBP12 in patient tissues and cancer cell lines. In patient samples, ACTBP12 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
